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INTRODUCTION 
Somatostatin has been demonstrated in high concentrations in the hypothalamus, 
the cerebral cortex, the brain stem, the gastrointestinal tract, and the pancreas. In the 
central nervous system, it acts as a neurotransmitter, whereas its hormonal activities 
include the inhibition of the release of growth hormone, insulin, glucagon, and 
gastrin (for a review, see ref. 1). Also, antiproliferative effects have been reported, 
both in vitro on tumor cell lines, and in vivo on neuroendocrine human tumors. 
High-affinity somatostatin receptors have been identified in the brain and on 
many cells of neuroendocrine origin, like the somatotroph cells of the anterior 
pituitary and the pancreatic islet  cell^.^.^ Also, cells not known classically as neu- 
roendocrine, such as lymphocytes, may possess these  receptor^.^ Besides, somatos- 
tatin receptors have been demonstrated on a variety of human tumors by classical 
biochemical binding techniques, as well as by in vitro autoradiography. These 
tumors include those with APUD (amine precursor uptake and decarboxylation) 
characteristics (pituitary tumors, endocrine pancreatic tumors, carcinoids, paragan- 
gliomas, small cell lung cancers, medullary thyroid carcinomas, pheochromocy- 
tomas} as well as meningiomas, well-differentiated brain tumors (astrocytomas), 
neuroblastomas, and some human breast cancers. 
Because of the short plasma half-life of somatostatin (2-4 min), analogues more 
suitable for medical treatment have been developed. The somatostatin analogue, 
octreotide, has been shown to bind to somatostatin receptors on both tumorous and 
nontumorous tissues. 
An "'In-labeled somatostatin analogue ([DTPA-D-Phe'l-octreotide] was devel- 
oped for its use in scintigraphy. [DTPA-D-Phe'l-octreotide was shown to bind "'In 
efficiently in a single-step labeling procedure. The binding as well as the biological 
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activity of this new radionuclide was shown to be similar to that of octreotide, 
making it a good radiopharmaceutical for in vivo imaging of somatostatin receptor- 
positive t ~ m o r s . ~  [lllIn-DTPA-~-Phel]-octreotide is excreted mainly through the 
kidneys, 90% of the dose being present in the urine 24 h after injection." 
[ "lIn-DTPA-~-Phe']-octreotide (OctreoScan 11 l@), scintigraphy was performed 
in more than 1000 patients at the University Hospital Rotterdam (UHR), without any 
side effects being noticed.' To avoid a paradoxical hypoglycemia, the only precau- 
tion taken was a glucose-infusion in case of an insulinoma if the response to 
octreotide was unknown beforehand. 
In this report, European data of octreotide scintigraphy of GEP tumors are 
reviewed. Because of the frequent localization of these (small) tumors in the upper 
abdomen where their presence (recognition) may be obscured by the physiologic 
accumulation of radioactivity, especially in kidneys, liver, and spleen, it seems that 
for this type of tumor the protocol of scintigraphy is of the utmost importance. 
PROTOCOL OF [lllIN-DTPA-~-PHE1]-OCTREOTIDE SCINTIGRAPHY 
AT UNIVERSITY HOSPITAL ROTTERDAM 
The preferred dose of "'In is about 200 MBq, coupled to 10 pg ( D T P A - D - P ~ ~ ~ I -  
octreotide. With such a dose, it is possible to perform single photon emission 
computerized tomography (SPECT), that is "CT in nuclear medicine," which may 
increase the sensitivity for detecting octreotide receptor-expressing tissues and 
which gives a better anatomical delineation than planar views. This is especially the 
case if the lesion(s) is (are) located in the skull or abdomen. 
Planar and SPECT images are obtained with a large-field-of-view gamma cam- 
era, equipped with a medium-energy parallel-hole collimator. The pulse height- 
analyzer windows are centered over both "'In photon peaks (172 kev and 245 kev) 
with a window width of 20%. Data from both windows are added to the acquisition 
frames. The acquisition parameters are for planar images (anterior and posterior 
views necessary!): (1) 128 x 128 word matrix, (2) images of headheck: 300,000 
preset counts (or max. 15 min) at 24 h and 15 min present time (= 200,000 counts) 
at 48 h after injection, (3) the remainder of the body with separate images of the chest 
(including as little as possible of the liver and spleen (!) and, in case of suspicion of 
metastases in the armpits, projections of the shoulders with upraised arms), the upper 
abdomen (including liver/spleen and kidneys), and lower abdomen: 500,000 counts 
(or max. 15 min). For SPECT images, these parameters are (A) single-head camera, 
(1) 60 projections, (2) 64 x 64 word matrix, (3) at least 45-60 second acquisition time 
per projection; or (B) three-head camera, (1) 120 projections, (2) 64 x 64 word 
matrix, (3) at least 30 seconds acquisition time per step (45 seconds for SPECT of 
the head). In case the counting time to obtain these counts for the planar views is 
short, especially when tissues with relatively high accumulation (e.g. abdominal 
organs) are included in the field of view, additional images with a longer counting 
time (up to 15 min per planar view) are necessary in order to visualize also lesions 
with low somatostatin receptor density. The above-mentioned counting times per 
projection for planar imaging with a single-head camera also imply an appropriate 
(long) duration of whole body scintigraphy with a dual-head camera, for example, 
at least 30 min from head up to and including the pelvis. SPECT studies are 
inevitable, especially if (small) tumors are located in the abdomen and not visualized 
on planar images, because of overprojection by other tissues or organs. Examples are 
islet cell tumors in the head or tail of the pancreas and tumors in the (hilus of) the 
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liver. In special cases, after obtaining an initial negative SPECT study, for example, 
in which the tumor might be very small or express a low density of ligand receptors, 
another SPECT study with a longer counting time per step might be indicated in the 
same session or on another day, thus using the same administered radioligand. In 
general, the more counts that are being collected, the better are the results in detecting 
or localizing ligand receptor-expressing tissue(s). SPECT analysis is performed with 
a Wiener filter on original data. The filtered data are reconstructed with a Ramp filter. 
Planar and SPECT studies are preferably performed 24 h after injection of the 
radiopharmaceutical. Planar studies after both 24 and 48 h can be camed out with 
the same protocol. Repeat scintigraphy after 48 h is especially indicated when 24 h 
scintigraphy shows accumulation in the abdomen, which may also represent radio- 
active bowel content. Four-hour images of the abdomen are recommended by others 
because at that time radioactive bowel content is almost always absent. One should 
realize that the relative high background radioactivity at 4 h might obscure the 
localization of lesions with low-receptor density at this moment, however. These 
lesions may be visible at 24 h, because of a six times lower bloodpool radioactivity 
at 24 h after injection of the radioligand and a relatively long, effective half-life of 
the radiolabel in the tumor. This difference in results of 4 and 24 h images neces- 
sitates scanning after 48 h, inasmuch as the interpretation of the difference in 
abdominal accumulation is twofold: radioactive bowel content or the accumulation 
in a lesion with low-receptor density. If the abdomen is (also) the region of interest, 
the use of laxatives is highly recommended, starting from the moment of injection. 
RESULTS 
TABLE 1 illustrates the results of [IL1In-DTPA-~-Phe1]-octreotide scintigraphy in 
patients with gastroenteropancreatic (GEP) tumors and those of autoradiography 
with [ 1251-Ty?]-~~tre~tide. Scintigraphic investigations were carried out at fifteen 
TABLE 1. Scintigraphy with [L1lIn-DTPA-~-Phe']-Octreotide in Gastroenteropancrea- 
tic Tumorso 
EMT EUR Combined Autoradiography 
Carcinoids 
Gastrinomas 
Insulinomas 
Motilinomas 
Nonsecreting tumors 
Glucagonomas 
VIPomas 
Total 
Pancreatic 
adenocarcinomas 
87% (182) 
73% (67) 
46% (24) 
111 
82% (60) 
100% (5) 
88% (8) 
(81%) 
2811347 
96% (72) 
61% (23) 
89% (18) 
100% (3) 
112 
1151130 
(88%) 
0% (24) 
100% (12) 
89% 88% (62) 
77% 100% (6) 
53% 67% (27) 
83% 100% (4) 
100% 100% (2) 
80% 
3961477 
(83%) 
0% (12) 
@Results of the European Mallinckrodt Trial (EMT) (including 15 centers), the Erasmus 
University Rotterdam (EUR) (ref. 7), and the combined data of EMT and EUR. Auto- 
radiographic ([125LTyr3]-octreotide) data (Dr. J. C. Reubi) are based on tumor samples from 
other patients than mentioned in the scintigraphic results. See also remarks in PROTOCOL 
and DISCUSSION. 
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centers in various countries in Europe (collected in the "European Mallinckrodt 
Trial") (EMT) and at the University Hospital Rotterdam (UHR), respectively. 
The differences in results between the EMT and UHR are less than 10% for 
carcinoids, nonsecreting endocrine pancreatictumors, and glucagonomas, whereas 
gastrinomas and insulinomas show a larger difference in sensitivity. The a priori 
chance, based on in vitro autoradiography with radiolabeled octreotide, of obtaining 
a positive octreoscan in a patient with a gastrinoma is 100 percent (TABLE 1). 
Actually the a priori chance might be lower in a patient with a suspicion (i.e., based 
on endocrine testing) of having a gastrinoma, because not every patient with this 
suspicion will have a gastrinoma. The distribution of the primary sites of pancreatic 
and duodenal gastrinomas, found by one or more of the applied imaging techniques 
in the EMT and at the EUR (n = 46), was as follows: pancreas 87%, and duodenum 
13%, of which ['I'In-DTPA-~-Phe']-octreotide scintigraphy was positive in 90% and 
50%, respectively. In the EMT, conventional imaging modalities (CIM), mainly CT 
scanning, were able to localize tumor(s) in 50 out of 67 (75%) patients with a strong 
clinical suspicion of having a gastrinoma. Octreotide scintigraphy of the lesions 
found by CIM was positive in 42 out of 50 (84%) patients, while octreotide scintig- 
raphy found additional lesions in about 40% of these patients. In the 8 patients with 
positive CIM and negative octreotide scintigrams, tumor localization, according to 
CIM was as follows: pancreas (3), duodenum (3), liver hilus, and liver. In 6 out of 
8 (75%) of these patients 1. the dose of ["'In-DTPA-o-Phe']-octreotide was between 
100 and 129 MBq and/or 2. no abdominal SPECT had been performed. In the 
CIM-negative patients, octreotide scintigraphy demonstrated (a) lesion(s) in 6 out of 
17 (35%) patients. The combination of CIM and octreotide scintigraphy localized 
lesions in 56 out of 67 (84%) patients with a suspicion of having a gastrinoma. 
The a priori chance, based on autoradiography with radiolabeled octreotide, of 
obtaining a positive octreoscan in a patient with an insulinoma is 67 percent (TA- 
BLE 1). In the EMT patients with a suspicion of having an insulinoma, 17 out of 24 
(71%) had a lesion found by CIM, whereas 9 out of 17 (53%) had a positive 
octreotide scintigram. In 3 out of 8 (38%) negative octreoscan patients, the dose of 
["'In-DTPA-D-Phe'l-octreotide was between 103-123 MBq, and no abdominal 
SPECT had been performed. In the CIM-negative patients, octreotide scintigraphy 
found a lesion in 2 out of 7 (29%) patients. The combination of CIM and octreotide 
scintigraphy localized lesions in 19 out of 24 (79%) patients with a strong clinical 
suspicion of having an insulinoma. 
TABLES 2 and 3 show the CIM and octreotide scintigraphy results of EMT and 
UHR in gastrinomas and insulinomas in comparison with a recent overview of 
results of imaging techniques reported in the l i t e ra t~re .~ .~  
DISCUSSION 
A comparison of the results obtained at the University Hospital Rotterdam 
(UHR) and another fifteen centers in Europe (collected in the European Mallinckrodt 
Trial) (EMT) shows a few remarkable similarities and differences. The overall 
sensitivity of [ "'In-DTPA-~-Phel]-octreotide scintigraphy for detecting the primary 
GEP tumor and its metastases is high, for example, 80-90 percent. The sensitivity 
of this scanning technique for tumors generally expressing a high density of octreo- 
tide receptors, for example, carcinoids, glucagonoma, and the so-called "nonsecret- 
ing" pancreatic endocrine tumors, is very high, and the difference in results in both 
groups of centers is less than ten percent. Apparently, the below-mentioned differ- 
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TABLE ZA. Primary Gastrinoma" 
Sensitivity Range Specificity 
Procedure Mean (percent) (percent) Mean (percent) Range 
us 23 21-28 92 92-92 
CT scan 50 35-59 90 83- 100 
Angiography 68 35-68 89 84-94 
IOUS 83 
MRI 21 33 
PVS 73 33 
Intraarterial 
Secretin test 78 55-100 100 
Transillumination of duodenum 83 88 
Endoscopic US (only upper 86 
CIM in EMT 75 
Octreoscan 77 73-100 
(only duodenal gastrinorna) 
abdomen) 
Sensitivity and specificity of various imaging modalities to localize the primary and 
metastases of gastrinomas (modified from an overview in ref. 8, based on data reported in the 
literature; ref. 9; and this report (results of conventional imaging techniques (CIM), mainly 
based on CT scanning in the European Mallinckrodt Trial (EMT) and [llLIn-DTPA-~-Phel]- 
octreotide scintigraphy in EMT and EUR). See TABLE 1. US = ultrasound; IOUS = in- 
traoperative US; PVS = selective gastrin sampling from portal venous tributaries. 
ences in scanning procedure are not that relevant for the sensitivity of ["IIn-DTPA- 
o-Phel]-octreotide scintigraphy in these types of tumors. On the other hand, a 
difference of 15% and higher in sensitivity has been found for the insulinomas and 
gastrinornas, respectively. A closer look at the scanning procedure used at UHR and 
EMT, reveals a few remarkable differences, which might explain the contrasting 
findings in the insulinoma and gastrinoma patients, inasmuch as the presence of 
octreotide receptors in insulinomas is not 1 0 % ,  as is the case in gastrinomas, but 
about sixty-five percent. Also, a bias of patient selection might be involved in the 
difference in sensitivity for the insulinomas. Probably, the same might hold for 
differences in the endocrine inclusion criteria applied for both the gastrinomas and 
insulinornas. The major differences in the scanning protocol were fourfold: In the 
TABLE ZB. Metastases of Gastrinomao 
Procedure 
Sensitivity Range Specificity 
Mean (percent) (percent) Mean (percent) Range 
us 14 14-63 100 
CT scan 54 35-72 99 98-100 
Angiograph y 62 33-86 98 96-100 
IOUS NE NE 
MRI 67 100 
PVS NE NE 
'See legend for TABLE 2A. 
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TABLE 3. Insulinomasa 
Procedure 
Sensitivity 
Mean (percent) 
us 
CT scan 
Dynamic CT scan 
Selective arteriography 
All imaging studies 
Transhepatic portal venous sampling 
Operative US 
Endoscopic US (only upper abdomen) 
CIM in EMT 
Octreoscan 
33 
35 
66 
63 
80 
92 
81 
71 
53 
83-90 
Range 
(percent) 
0-66 
11-50 
17-100 
50-90 
89-96 
46-61 
%Sensitivity and specificity of various imaging modalities to localize the primary of in- 
sulinomas (modified from an overview in ref. 8, which is based on data reported in the 
literature, including data from ref. 9 and this report). See legend for TABLE 2A. 
EMT false-negative ['LLIn-DTPA-~-Phel]-octreotide, scintigrams have especially 
been obtained in patients who were (1) injected with a much lower dose of IllIn 
(-labeled ligand) and (2) not investigated with SPECT. (3) If SPECT was applied, 
the counting time per projection/view or step was much shorter than the time used 
at UHR. Furthermore most of our SPECT studies have been performed with a 
three-head gamma-camera, which has several advantages over the usual one-head 
gamma-camera, for example, a higher sensitivity. SPECT is absolutely necessary in 
cases in which tumor radioactivity on planar images is or might be obscured by 
overprojection of radioactivity originating from other organs or tissues (FIG. 1). 
Examples are the small endocrine tumors and/or octreotide receptor+xpressing 
tumors with low-receptor density localized in the head and/or tail of the pancreas, 
duodenum, or hilus of the liver. In these cases the planar images of ["IIn-DTPA- 
~-Phe']-octreotide scintigraphy may miss the abnormalities in contrast to the SPECT 
images, because of their view on the tumor from different angles. Also in these cases 
it is important to underline that the longer the counting time (both for planar and 
SPECT imaging), the more information is being collected and the higher is the 
chance to localize a tumor (FIG. 2). Therefore, peptide-receptor scintigraphy requires 
a learning process both for the technician and for the nuclear medicine physician. The 
above-mentioned protocol can serve as a guide in this process. 
In contrast to the UHR patients with insulinomas and gastrinomas, a high pro- 
portion of such patients in the EMT might have been asked to undergo octreotide 
scintigraphy while they were already diagnosed, and their tumor(s) localized for a 
longer time. This might explain the high proportion of patients (with larger tumors 
than at the time of first referral?) localized with CIM, mainly by CT scanning. This 
is especially the case if the CIM sensitivities (7&75%) of the EMT are being 
compared with those of the (TABLES 2 and 3). Of course this might also 
influence in a positive way the results of octreotide scintigraphy. Nevertheless 
octreotide scintigraphy was able to localize (1) additional metastases in about one 
third of the CIM-positive group of patients and (2) lesions in about one third of the 
CIM-negative group of patients with a strong clinical suspicion of having an in- 
sulinoma or gastrinoma. 
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FIGURE 1. Two examples of octreotide scintigraphy in patients with an insulinoma (a) and 
a gastrinoma (b) of which the anterior and posterior planar abdominal images did not show 
a lesion (not shown). The SPECT images, that is, the right-sided images in a and b, illustrate 
the actual localization of the tumors. SPECT studies are inevitable, especially if (small) tumors 
are located in the abdomen and not visualized on planar images and because of overprojection 
by other tissues or organs. Examples are islet cell tumors in the head or tail of the pancreas 
and tumors in the (hilus of) the liver. In these cases, the planar images of [IILIn-DTPA-D- 
PHE'I-octreotide scintigraphy may miss the abnormalities in contrast to the SPECT images 
because of their view on the tumor from different angles. In a, L = liver, S = spleen, K = 
kidney, and T = tumor. 
FIGURE 2. The longer the counting tim
e (both for planar and SPECT im
aging), the m
ore inform
ation is being collected and the higher is the chance 
to localize a tum
or w
ith octreotide scintigraphy. The tw
o
 planar octreotide scintigram
s (pastenor thoracic-abdom
inal view
s) have been obtained in 
a consecutive w
ay from
 the sam
e patient w
ith a history of breast cancer. The left im
age (3 m
in counting tim
e) only show
s a hotspot just above the 
spleen, w
hereas the right im
age (15 m
in counting tim
e) show
s this hotspot not only m
ore intense, but also several spots in the spinal colum
n and the 
chest, representing proven m
etastases of som
atostatin receptorexpressing breast cancer. 
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